Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a report of 13 cases and review of the literature
- 16 July 2010
- journal article
- case report
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 82 (3) , 306-308
Abstract
Background A few case reports have shown controversial results of rituximab efficacy in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Objective To analyse the efficacy of rituximab in a large CIDP cohort. Methods A retrospective, observational and multicentre study on the use of rituximab in CIDP. 13 Italian CIDP patients were treated with rituximab after the partial or complete lack of efficacy of conventional therapies. Eight patients had co-occurring haematological diseases. Patients who improved by at least two points in standard clinical scales, or who reduced or discontinued the pre-rituximab therapies, were considered as responders. Results Nine patients (seven with haematological diseases) responded to rituximab: six of them, who were non-responders to conventional therapies, improved clinically, and the other three maintained the improvement that they usually achieved with intravenous immunoglobulin or plasma exchange. Significantly associated with shorter disease duration, rituximab responses started after a median period of 2.0 months (range, 1–6) and lasted for a median period of 1 year (range, 1–5). Conclusions Rituximab seems to be a promising therapeutic choice when it targets both CIDP and co-occurring haematological diseases. Timely post-onset administration of rituximab seems to be associated with better responses.Keywords
This publication has 16 references indexed in Scilit:
- Placebo‐controlled trial of rituximab in IgM anti–myelin‐associated glycoprotein antibody demyelinating neuropathyAnnals of Neurology, 2009
- Current treatments of chronic immune‐mediated demyelinating polyneuropathiesMuscle & Nerve, 2009
- Rituximab efficacy in CIDP associated with idiopathic thrombocytopenic purpuraMuscle & Nerve, 2008
- Predictors of response to rituximab in patients with neuropathy and anti–myelin associated glycoprotein immunoglobulin MJournal of the Peripheral Nervous System, 2007
- Rituximab in chronic inflammatory demyelinating polyneuropathy associated with diabetes mellitusJournal of the Neurological Sciences, 2007
- Rituximab treatment in patients with IVIg‐dependent immune polyneuropathy: A prospective pilot trialMuscle & Nerve, 2006
- Rituximab therapy in monoclonal IgM-related neuropathiesLeukemia & Lymphoma, 2006
- Rituximab‐responsive CIDPEuropean Journal of Neurology, 2004
- Sustained remission of CIDP associated with Evans syndromeNeurology, 2004
- EBV‐associated lymphoma and chronic inflammatory demyelinating polyneuropathy in an adult without overt immunodeficiencyAmerican Journal of Hematology, 2002